Emtricitabine

4 papers7 findings

PubChem 60877 ChEBI 31536 MeSH D000068679

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 1 country

Funders: National Institute of Arthritis and Musculoskeletal and Skin Diseases and 2 more

Animals2
Cells2

Outcomes

Cellular senescence

upin mouse cells2upin human cells1

2 studies

Emtricitabine induces cellular senescence in mouse cells.
“FTC, alone or in combination with other ART (tenofovir alafenamide and tenofovir disproxil fumarate), activated AhR and induced senescence of female myoblasts”
Cellsmyoblastsfemales
The antiretroviral drug emtricitabine increases kynurenine: tryptophan ratio, aryl hydrocarbon receptor activation, and cellular senescence in female mice
Biochimie28 Dec 2025
Emtricitabine increases cellular senescence in human cells.
“showing increased expression of AhR, AhR target genes, and increased senescence in both cell populations.”
Cellsin primary human mesenchymal stem cells and myoblasts
THE AHR AS A POTENTIAL MEDIATOR OF MUSCULOSKELETAL FRAILTY WITH ANTI-RETROVIRAL THERAPY
GSA 2024 abstract31 Dec 2024
Emtricitabine increases cellular senescence in mouse cells.
“FTC, but not TDF, increased transcriptional activity of AhR, expression of AhR and its target gene CYP1A1, and increased cellular indicators of senescence.”
Cellsin C2C12 mouse myoblasts
THE AHR AS A POTENTIAL MEDIATOR OF MUSCULOSKELETAL FRAILTY WITH ANTI-RETROVIRAL THERAPY
GSA 2024 abstract31 Dec 2024